Short answer · Medically reviewed summary · Last updated: 2026-05-08
Cohen Syndrome is a rare genetic disorder caused by mutations in the VPS13B (formerly COH1) gene, which plays a critical role in intracellular protein trafficking. It is an autosomal recessive condition, meaning an individual must inherit two copies of the mutated gene—one from each parent—to develop Cohen Syndrome. What causes Cohen Syndrome at the genetic level? Cohen Syndrome is primarily caused by pathogenic variants in the VPS13B gene located on chromosome 8q22.2.
3 people with Cohen Syndrome have shared their first-person experience on this question at DiseaseMaps.
Cohen Syndrome is a rare genetic disorder caused by mutations in the VPS13B (formerly COH1) gene, which plays a critical role in intracellular protein trafficking. It is an autosomal recessive condition, meaning an individual must inherit two copies of the mutated gene—one from each parent—to develop Cohen Syndrome.
Cohen Syndrome is primarily caused by pathogenic variants in the VPS13B gene located on chromosome 8q22.2. Think of this gene as an instruction manual for a cell’s internal shipping department. When the VPS13B gene is mutated, the cell struggles to transport proteins correctly between different compartments, specifically within the Golgi apparatus. This disruption in cellular "logistics" leads to the multisystem clinical presentation characteristic of Cohen Syndrome, including developmental delays and distinct craniofacial features.
Yes, Cohen Syndrome follows an autosomal recessive inheritance pattern. This means that if both parents are carriers of a VPS13B mutation, there is a 25% chance with each pregnancy that the child will be born with Cohen Syndrome. Because it is genetic, there are no known environmental triggers, infections, or autoimmune processes that cause the condition.
It is important to distinguish between causes and risk factors in Cohen Syndrome:
Research is ongoing to understand exactly how VPS13B protein dysfunction leads to specific symptoms like neutropenia (low white blood cell count) and retinal dystrophy. Scientists are currently using cellular models to explore potential therapies that could stabilize protein transport pathways.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.